CLPT - ClearPoint Neuro, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

CLPT

CLEARPOINT NEURO, INC.

NASDAQ

$15.55

▼ DOWN 2.45% (-0.39)

KEY STATISTICS

Market Cap$466.34 M

52w High$30.10

52w Low$8.27

Dividend Yield—

Frequency—

P/E-13.18

Volume467.52K

Shares Out.29.99M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Joseph Michael Burnett

COMPENSATION 2026

Salary$325,000

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$9,994

Total$334,994

ABOUT

SECTOR

Healthcare

WENT PUBLIC

May 22, 2012

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

172

PRICE TARGET

Target High$25.00

Target Low$22.00

Target Median$23.50

Target Consensus$23.50

UPCOMING EARNINGS

DateNov 5, 2026

DayThursday

Rev. Est.$12.27M

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2016-07-27	Reverse	1:40

PRICE

$15.55 ▼ DOWN 2.45% (−$0.39)

OVERLAYS

About ClearPoint Neuro, Inc.

https://www.clearpointneuro.com ↗

ClearPoint Neuro, Inc. develops minimally invasive MRI-guided surgical platforms for brain procedures, including electrode placement, biopsies, and drug infusion, with collaborations across leading medical institutions.

INDUSTRY

Medical - Devices

A PRODUCT CLEARPOINT NEURO, INC. IS KNOWN FOR

SmartFlow® Cannula

ClearPoint Neuro's FDA-approved neuro-infusion cannula enables MRI-guided gene therapy delivery to the brain, marking a major advancement in neurological treatments and positioning the company as a leader in the growing gene therapy market.

COMPETITORS

COMPETITOR

Revenue by Products

PRODUCT	Q2-2025	Q3-2025	Q1-2026	Q2-2026
Biologics And Drug Delivery	$4.74M	$4.4M ▼	$4.81M ▲	$4.03M ▼
Capital Equipment And Software	$1.04M	$1.04M ▼	$1.43M ▲	$1.3M ▼
Biologics And Drug Delivery Disposable Products	$1.87M	$1.29M ▼	$1.9M ▲	$943K ▼
Capital Equipment And Software Systems and Software Products	$694K	$647K ▼	$1.02M ▲	$881K ▼
Capital Equipment And Software Services	$350K	$390K ▲	$413K ▲	$416K ▲